A new drug targeting two 'hotspots' on a protein linked to Alzheimer's disease could offer fresh hope for millions living with the condition. The medication, called RI-AG03, tackles tau proteins which clump together and form harmful tangles in the brain, slowing down signals and eventually killing neurons.
READ MORE: Drs thought my husband was depressed..it was actually dementiaA first-of-its-kind drug that tackles toxic protein tangles in the brain in Alzheimer's patients could provide fresh hope to millions living with the disease.
The medicine targets tau proteins which normally play a crucial role in maintaining brain cell health. She said that 'for the first time', we have a drug which is effective in slowing the formation of tau tangles. 'By targeting both of the key areas on the tau protein, this unique approach could help address the growing impact of dementia on society, providing a much-needed new option for treating these devastating diseases.'
The team also carried out experiments in human cells in the lab and found similar evidence it reduced tau clumping. Last year, the medical world rejoiced as the first drug to clearly slow the progression of Alzheimer's was approved in the US.
Alzheimer's Dementia New Drug Protein Tangles Brain Health
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Northampton Market returns home after £10m faceliftThe historic market has new stalls from Italy, new paving, new lighting and new trees.
Read more »
Cosmochemistry techniques shed light on potential new Alzheimer's disease biomarkerThe study identifies lower potassium isotope ratios in Alzheimer's patients, suggesting δ41K as a viable biomarker for early detection of the disease.
Read more »
A new biomarker makes it easier to distinguish between Alzheimer's and primary tauopathyPatients regularly show up at university hospitals with diseases so rare and specific as to be scarcely known to physicians in private practice. Primary 4-repeat tauopathies are a good example.
Read more »
New therapy that targets and destroys tau tangles: A promising Alzheimer's disease treatmentScientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.
Read more »
New biomarker helps differentiate Alzheimer’s from primary 4-repeat tauopathiesA new biomarker makes it easier to distinguish between Alzheimer's and primary tauopathy.
Read more »
Astrocytes study identifies a new therapeutic target for Alzheimer's diseaseWorldwide, at least 50 million people are believed to be living with a form of dementia. Alzheimer's disease is the most common type of dementia. It is a progressive and irreversible neurodegenerative disorder that primarily affects memory and cognitive functions.
Read more »